CD8A and non-small cell lung carcinoma: Additionally, combinational therapy blocking both TIGIT and PD-L1 showed slightly better OS in patients with NSCLC compared to a control group receiving anti-PD-L1 plus placebo; CD8+ effector TILs were associated with improved ORR in patients receiving both ICB agents [55].